Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study
Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials. We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt. Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV. Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.
Authors
- Marina Bruck (ORCID: https://orcid.org/0000-0002-0227-9768)
- Felipe Lobelo (ORCID: https://orcid.org/0000-0003-4185-7193)
- David C. Benkeser (ORCID: https://orcid.org/0000-0002-1019-8343)
- Elizabeth T. Rogawski McQuade (ORCID: https://orcid.org/0000-0002-4942-3747)
- Mackenzie Crawford (ORCID: https://orcid.org/0009-0002-6191-2831)
- Sara S. Kim (ORCID: https://orcid.org/0000-0002-1056-9896)
- Alexander F. Hudgins (ORCID: https://orcid.org/0000-0002-8980-3330)
- Emily Wu
Institutions
- Kaiser Permanente (US)
- Emory University (US)
- Colorado Permanente Medical Group (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-15
- DOI
- https://doi.org/10.64898/2026.11.12.26367940
- Primary Topic
- Respiratory viral infections research
- Type
- preprint